GILEAD NASH Trial

Objective: To evaluate the safety and tolerability of GS-0976 in subjects with nonalcoholic steatohepatitis (NASH) as assessed by magnetic resonance imaging proton-density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE).

GS-0796 is a small molecule allosteric inhibitor that acts at the protein-protein homodimer interface of acetyl Co-A carboxylases ACC1 and ACC2, to prevent dimerization. ACC1 catalyzes the first step of the de novo lipogenesis (DNL) by converting acetyl CoA to malonyl CoA while ACC2 regulates the entry of fatty acids into the mitochondria where beta oxidation can occur. Therefore, inhibition of ACC1 and ACC2 will reduce DNL and increase fatty acid beta oxidation.

Participation in the study can last up to 21 weeks, including a 4-week Screening period, a 12-week treatment period during which study drugs will be administered, and a 4-week follow-up period. Subjects meeting the study’s entry criteria will be randomized assigned in a 2:2:1 ratio to 3 treatment groups, as follows:

Inclusion Criteria:

  • A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD) with imaging documenting fatty liver within two years prior to screening. If necessary an ultrasound may be performed during screening to confirm NAFLD.
  • Screening MR-PDFF with ≥ 10 % steatosis.
  • Screening MRE with liver stiffness ≥ 2.90 kPa.

Please note: Historical biopsies within 1 year can be used for study entry. All patients will receive study drug as described above.

Principal Investigator: Dr. Hillel Tobias, MD. PhD.
Please contact the Clinical Trials Team if you have any potential patients.
Resmi: (212) 889-5544 Ext. 152
Email: Rvarughese@concordemed.com

Communication

Contact Us

Quick Contact

  • This field is for validation purposes and should be left unchanged.


Convenience

Our NYC Locations

232 East 30 Street
New York, NY 10016

233 Broadway
Suite 840
New York, NY 10279

100 Crosby Street
Suite 406
New York, NY 10012

26 Court Street
Suite 808
Brooklyn, NY 11242